Rare diseases
Investigational molecules
Locations
Pipotiazine palmitate is an antipsychotic medicine. It belongs to the group of medicines used to treat conditions that involve psychosis, such as schizophrenia. The substance appears in the EU trial records under two names: pipotiazine palmitate for the long-acting injection and pipotiazine for the oral form.[1] The trade name Piportil is used for a solution for injection containing pipotiazine 100 mg/4 ml.[2] Pipotiazine is authorised as a medicine in some countries, although the specific authorisation details are not given in these records.[1]
Pipotiazine is an antipsychotic. The available sources do not describe its exact mechanism of action in detail. Antipsychotic medicines of this type are generally used to reduce symptoms such as hallucinations and delusions, but the specific molecular target of pipotiazine is not stated in the provided sources.
Pipotiazine is available in two forms in the trial records: an intramuscular injection of pipotiazine palmitate and an oral form of pipotiazine. The injection form is a long-acting depot preparation, while the oral form is given as tablets.[1] The product information for Piportil describes a solution for injection containing 100 mg in 4 ml.[2] DrugCentral lists oral and parenteral dose forms.[3]
One Phase 3 trial is listed in the EU Clinical Trials Information System. It is a prospective, randomised, controlled study with 288 participants.[1] The trial compares two treatment strategies in people with schizophrenia spectrum disorders: dose reduction of antipsychotics versus maintenance treatment.[1] Pipotiazine palmitate and pipotiazine are among 14 antipsychotic drugs that may be used in the study, depending on the treatment arm and the participant's clinical situation.[1]
The main outcome measure is the percentage of patients with functional remission, defined as a score above 70 on the Personal and Social Performance Scale (PSP) at 24 months. The PSP is a scale that measures how well a person functions socially and personally. The score is assessed both by the treating psychiatrist and by an independent evaluation team that is blinded to the treatment arm.[1]
The trial is currently authorised, meaning it has received approval to begin or continue.[1]
The provided sources do not list specific side effects for pipotiazine palmitate. DrugCentral notes that the substance is used in veterinary medicine as well as in humans, but does not provide a side effect profile in the extracted content.[3]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
